Cargando…

TRIM24介导肺癌细胞吉非替尼耐药机制探讨

BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance signifcantly limits its use in clinical practice. Study found that TRIM24 was overexpressed in non-small cell lung cancer (NSCLC) tissues and regulate cell growth, cell cycle and apoptosis in l...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999805/
https://www.ncbi.nlm.nih.gov/pubmed/26805734
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.01.03
_version_ 1783331514759512064
collection PubMed
description BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance signifcantly limits its use in clinical practice. Study found that TRIM24 was overexpressed in non-small cell lung cancer (NSCLC) tissues and regulate cell growth, cell cycle and apoptosis in lung cell lines. Te aim of this study is to explore the mechanism of TRIM24 to regulate resistance of Geftinib in NSCLC cells. METHODS: MTT and apoptosis were used to detect the change of cell grow and cell apoptosis with down-expression TRIM24 and ShTRIM24 with presence of Geftinib. Meanwhile, Western blot was used to detect the expression of protein related to apoptosis and AKT signal path. RESULTS: TRIM24 interference could improve the effect of gefitinib on cell growth inhibition and upregulate the cell apoptosis in A549 cell. Down-regulated of endogenous TRIM24 and ShTRIM24 with Giftinib could also reduce the protein related apoptosis, such as p-BAD and Bcl-2, and the protein PIK3CA related AKT signal path in A549 cell. CONCLUSION: TRIM24 could regulate required resistance to Geftinib via Akt pathway in NSCLC.
format Online
Article
Text
id pubmed-5999805
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59998052018-07-06 TRIM24介导肺癌细胞吉非替尼耐药机制探讨 Zhongguo Fei Ai Za Zhi 基础研究 BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance signifcantly limits its use in clinical practice. Study found that TRIM24 was overexpressed in non-small cell lung cancer (NSCLC) tissues and regulate cell growth, cell cycle and apoptosis in lung cell lines. Te aim of this study is to explore the mechanism of TRIM24 to regulate resistance of Geftinib in NSCLC cells. METHODS: MTT and apoptosis were used to detect the change of cell grow and cell apoptosis with down-expression TRIM24 and ShTRIM24 with presence of Geftinib. Meanwhile, Western blot was used to detect the expression of protein related to apoptosis and AKT signal path. RESULTS: TRIM24 interference could improve the effect of gefitinib on cell growth inhibition and upregulate the cell apoptosis in A549 cell. Down-regulated of endogenous TRIM24 and ShTRIM24 with Giftinib could also reduce the protein related apoptosis, such as p-BAD and Bcl-2, and the protein PIK3CA related AKT signal path in A549 cell. CONCLUSION: TRIM24 could regulate required resistance to Geftinib via Akt pathway in NSCLC. 中国肺癌杂志编辑部 2016-01-20 /pmc/articles/PMC5999805/ /pubmed/26805734 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.01.03 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 基础研究
TRIM24介导肺癌细胞吉非替尼耐药机制探讨
title TRIM24介导肺癌细胞吉非替尼耐药机制探讨
title_full TRIM24介导肺癌细胞吉非替尼耐药机制探讨
title_fullStr TRIM24介导肺癌细胞吉非替尼耐药机制探讨
title_full_unstemmed TRIM24介导肺癌细胞吉非替尼耐药机制探讨
title_short TRIM24介导肺癌细胞吉非替尼耐药机制探讨
title_sort trim24介导肺癌细胞吉非替尼耐药机制探讨
topic 基础研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999805/
https://www.ncbi.nlm.nih.gov/pubmed/26805734
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.01.03
work_keys_str_mv AT trim24jièdǎofèiáixìbāojífēitìnínàiyàojīzhìtàntǎo
AT trim24jièdǎofèiáixìbāojífēitìnínàiyàojīzhìtàntǎo
AT trim24jièdǎofèiáixìbāojífēitìnínàiyàojīzhìtàntǎo
AT trim24jièdǎofèiáixìbāojífēitìnínàiyàojīzhìtàntǎo
AT trim24jièdǎofèiáixìbāojífēitìnínàiyàojīzhìtàntǎo